miR-92a inhibitor

miR-92a inhibitors are a class of RNA-based therapeutics, typically antisense oligonucleotides or antagomirs, designed to silence the activity of microRNA-92a. Research from the Brigham and Women’s Hospital and Harvard Medical School has identified miR-92a as a critical regulator of the immune balance in central nervous system (CNS) autoimmune diseases like multiple sclerosis (MS). miR-92a is often elevated in MS patients and promotes neuroinflammation by inhibiting the transcription factor Foxo1, which in turn suppresses the development of regulatory T cells (Tregs) and enhances the differentiation of inflammatory Th17 cells. Preclinical studies in experimental autoimmune encephalomyelitis (EAE) models have demonstrated that miR-92a inhibition can attenuate disease severity by recalibrating the Treg/Th17 ratio, suggesting its potential as a therapeutic strategy for autoimmune disorders.

Other names

miR-92a antagomirmiR92a antagomirmiR 92a antagomirantimiR-92aantimiR92aantimiR 92amicroRNA-92a inhibitormicroRNA92a inhibitormicroRNA 92a inhibitor